United Services Automobile Association lifted its stake in shares of Obseva SA (NASDAQ:OBSV) by 132.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 26,480 shares of the company’s stock after purchasing an additional 15,080 shares during the period. United Services Automobile Association owned 0.07% of Obseva worth $335,000 at the end of the most recent quarter.
Other hedge funds also recently modified their holdings of the company. Gables Capital Management Inc. purchased a new position in shares of Obseva during the fourth quarter valued at about $25,000. Aisling Capital Management LP bought a new stake in Obseva during the fourth quarter worth about $17,551,000. Wedbush Securities Inc. bought a new stake in Obseva during the fourth quarter worth about $264,000. First Manhattan Co. boosted its stake in Obseva by 38.2% during the fourth quarter. First Manhattan Co. now owns 2,117,112 shares of the company’s stock worth $26,802,000 after acquiring an additional 584,646 shares in the last quarter. Finally, VHCP Management III LLC bought a new stake in Obseva during the third quarter worth about $20,911,000. Institutional investors own 64.58% of the company’s stock.
OBSV stock traded up $0.40 during midday trading on Friday, reaching $13.90. 30,200 shares of the company’s stock traded hands, compared to its average volume of 39,772. Obseva SA has a 52-week low of $9.63 and a 52-week high of $20.35. The stock has a market cap of $613.98 million, a P/E ratio of -7.28 and a beta of 1.13.
OBSV has been the topic of several research reports. Wedbush set a $34.00 price objective on shares of Obseva and gave the stock a “buy” rating in a research note on Tuesday, January 15th. HC Wainwright set a $44.00 target price on shares of Obseva and gave the stock a “buy” rating in a research note on Friday, January 4th. ValuEngine upgraded shares of Obseva from a “hold” rating to a “buy” rating in a research note on Tuesday, April 9th. TheStreet downgraded shares of Obseva from a “c-” rating to a “d+” rating in a research note on Wednesday, January 16th. Finally, Zacks Investment Research raised shares of Obseva from a “sell” rating to a “hold” rating in a report on Friday, January 25th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $28.57.
Obseva Company Profile
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age.
Featured Story: Straddles
Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.